The stunning success of Novo Nordisk A/S's weight loss drug Wegovy has taken the head of the foundation that controls the Danish drugmaker by surprise, presenting it with the welcome challenge of what to do with the mountain of cash coming its way from the jaw-dropping launch.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?